{"entity":{"id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","aka":[],"tldr":"A swallowed sponge on a string can sample the oesophagus in a GP's office. Screen people with chronic reflux to catch adenocarcinoma at a curable stage.","summary":"The proposal is to screen adults with chronic reflux or long-term acid suppression for Barrett's oesophagus and early adenocarcinoma with a swallowed capsule sponge that can be given in a GP's office rather than by endoscopy. Oesophageal adenocarcinoma has a known precursor, a defined at-risk population and curative endoscopic resection for early disease; the missing piece has been an accessible test. In BEST3, reported in the Lancet in 2020, the Cytosponge-TFF3 test detected many more cases of Barrett's than usual care, and the NIHR-funded BEST4 trial now tests whether screening reduces deaths and shifts diagnosis to stage I. Being tested at scale, with EsoGuard methylation markers and AI histology as possible add-ons, it addresses the bottleneck that the hardest cancers are found late.","asOf":"2026-09-07","links":[{"label":"BEST3: Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus (Lancet 2020)","url":"https://doi.org/10.1016/S0140-6736(20)31099-0"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":[],"technologies":["endoscopic-resection","mced","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["barretts-esophagus","stage-shift"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-fitzgerald-lancet"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Offering capsule-sponge screening to adults on long-term acid suppression increases the proportion of oesophageal adenocarcinomas diagnosed at stage I and reduces oesophageal cancer mortality.","rationale":"Adenocarcinoma has a known precursor, a defined at-risk population, and curative endoscopic treatment for early disease; the missing piece is an accessible test.","test":"The BEST4 screening and surveillance arms (mortality and stage-shift endpoints) report in the late 2020s.","maturity":"being-tested-at-scale"},"route":"/ideas/idea-non-endoscopic-barretts-screening/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"term":[{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/"},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/"}],"paper":[{"id":"paper-fitzgerald-lancet","kind":"paper","name":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial","route":"/key-papers/paper-fitzgerald-lancet/"}],"bottleneck":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}]}}